iNtRON Biotechnology (048530) Fundamentals 2026 — Revenue Analysis | SniperIQ
iNtRON Biotechnology (048530) is a KR-listed Healthcare company in Biotechnology with a market capitalization of ₩76.0B, trading at ₩2460.00 on the KOE. This SniperIQ fundamentals page covers iNtRON Biotechnology's valuation, profitability (net margin -147.4%), revenue (₩5.7B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is iNtRON Biotechnology's market cap?
iNtRON Biotechnology (048530) has a market capitalization of approximately ₩76.0B, trading at ₩2460.00 on the KOE. Market cap moves with the live share price.
What is iNtRON Biotechnology's P/E ratio?
iNtRON Biotechnology's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is iNtRON Biotechnology?
iNtRON Biotechnology runs a net profit margin of -147.4%, a gross margin of 40.1%, and an operating margin of -127.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does iNtRON Biotechnology generate?
iNtRON Biotechnology reported revenue of ₩5.7B for fiscal year 2025, with net income of -₩9.3B and earnings per share (EPS) of -271.16. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does iNtRON Biotechnology pay a dividend?
iNtRON Biotechnology offers a trailing dividend yield of about 4.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is iNtRON Biotechnology financially healthy?
iNtRON Biotechnology carries a debt-to-equity ratio of 0.08x and a current ratio of 9.81x, with a market beta of 0.05. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is iNtRON Biotechnology a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For iNtRON Biotechnology (048530) the key facts are: market cap ₩76.0B, revenue ₩5.7B, 52-week range 2275-7010. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track iNtRON Biotechnology's full fundamentals live
Get iNtRON Biotechnology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.